eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Portal dla gastroenterologów!
SCImago Journal & Country Rank
vol. 13
Poleć ten artykuł:
streszczenie artykułu:

Meta-analysis of the efficacy and safety of pantoprazole in the treatment and symptom relief of patients with gastroesophageal reflux disease – PAN-STAR

Andrzej Dabrowski, Borut Štabuc, Leonid Lazebnik

Data publikacji online: 2018/03/26
Pełna treść artykułu
Pobierz cytowanie
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero

Proton pump inhibitors therapy success in the treatment of gastroesophageal reflux disease (GERD) is a difficult task because the extent of mucosal damage has no relation with the severity of the symptoms.

To establish the efficacy of pantoprazole treatment in patients with erosive reflux disease (ERD) and in those with non-erosive reflux disease (NERD), by assessing symptom relief and quality of life. Treatment duration and adverse events associated with pantoprazole treatment were analysed.

Material and methods
This meta-analysis was based on three multicentre, prospective, open-label, phase IV trials conducted in Slovenia, Poland, and the Russian Federation. In total, 252 patients with GERD were included and treated with pantoprazole 40 mg once daily for 4 or 8 weeks, depending on the fulfilment of predefined healing criteria. Symptoms were assessed by patients on a scale from 0 to 3 and the quality of life on a rating scale from 1 to 10.

Forty-five percent of patients fulfilled the healing criteria after 4 weeks of treatment, and 70% of patients after 8 weeks of treatment. Patients who failed to reach the healing criteria reported significant reduction of symptoms severity. The response to 8-week treatment was significantly higher in patients with ERD (76%) when compared to patients with NERD (64%). Discontinuation of treatment after 4 weeks was not associated with worsening of symptoms and did not affect quality of life. Pantoprazole treatment was associated with improvement of symptoms and the quality of life of GERD patients over 8 weeks of treatment and showed that GERD patients with persisting symptoms benefit from prolonging treatment to 8 weeks. Treatment with pantoprazole 40 mg was very well tolerated – more than 90% of patients were without adverse events throughout the whole study and only 4 patients discontinued the treatment due to adverse events related to pantoprazole treatment.

Pantoprazole 40 mg was associated with complete relief of GERD-related symptoms in the majority of patients with ERD and NERD. Furthermore, the severity of symptoms was significantly reduced in patients without complete relief of symptoms. Pantoprazole also continuously improved the quality of life of GERD patients over 8 weeks of treatment and was very well tolerated throughout the whole study. Therefore, this meta-analysis suggests that pantoprazole 40 mg once daily is an effective and well-tolerated choice for providing symptom relief of patients with GERD.

Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroentrol 2006; 101: 1900-20.
Dent J, El-Sareg HB, Wallander MA, Johansson S. Epidemiology of gastrooesophageal reflux disease: a systematic review. Gut 2005; 54: 710-7.
Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish Community. Am J Gastroenterology 2006; 101: 18-28.
Wahlqvist P, Brook RA, Campbell SM, et al. Objective measurement of work absence and on-the-job productivity: a case-control study of US employees with and without gastroesophageal reflux disease. J Occup Environ Med 2008; 50: 25-31.
Brook RA, Wahlqvist P, Kleinman NL, et al. Cost of gastrooesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol Ther 2007; 26: 889-98.
Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
Kulig M, Nocom N, Vieth M, et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGerd study. J Clin Epidem 2004; 57: 580-9.
Moayyedi P, Santana J, Khan M, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; 2: CD003244.
Wiklund I, Carlsson J, Vakil N. Gastroesofageal reflux symptoms and well-being in random sample of the general population of a Swedish community. Am J Gastroenterol 2006; 101: 18-28.
Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-33.
Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-91.
Gallo S, Dibildox M, Moguel A, et al. Clinical superiority of pantoprazole over ranitidine in the treatment of reflux esophagitis grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. Mexican Pantoprazole Study Group. Rev Gastroenterol Mex 998; 63: 11-6.
Dammann H, Von Kleist. Efficacy and tolerability of pantoprazole versus ranitidine and famotidine in patients with gastro-oesopghageal reflux disease: multicentre, open, randomised, control studies. International Clinical Practice Series 1997; 15: 23-9.
Richter JE, Bochenek W. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterology 2000; 95: 3071-80.
Van Rensburg CJ, Honiball PJ, Van Zyl JH, et al. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis – a 2-year follow-up. Aliment Pharmacol Ther 1999; 13: 1023-8.
Meneghelli UG, Boaventura S, Moraes-Filho JP, et al. Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate. Dis Esophagus 2002; 15: 50-6.
Armstrong D, Pare P, Pericak D, Pyzyk M. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96: 2849-57.
Richter JE, Fraga P, Mack M, et al. Prevention of erosive oeso­phagitis relapse with pantoprazole. Aliment Pharmacol Ther 2004; 20: 567-75.
Metz DC, Bochenek WJ. Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. Aliment Pharmacol Ther 2003; 17: 155-64.
Mathews S, Reid A, Tian C, Cai Q. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol 2010; 3: 11-6.
Fass R. Erosive esophagitis and nonerosive reflux disease (NERD) – comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007; 41: 131-7.
Kang JY. Systematic review: geographical and ethnic differences in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20: 705-17.
El Serag H, Bechler A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010; 32: 720-37.
Locke GR III, Talley NJ, Fett SL, et al. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999; 106: 642-9.
Mohammed I, Cherkas LF, Riley SA, et al. Genetic influences in gastro-oesophageal reflux disease: a twin study. Gut 2003; 52: 1085-9.
Bardhan KD, Achim A, Riddermann T, et al. A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving ‘complete remission’ in gastrooesophageal reflux disease. Aliment Pharmacol Ther 2007; 25: 1461-9.
Bardhan KD, Van Rensburg C. Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1585-91.
Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs 2008; 68: 925-47.
Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther 2005; 22: 79-94.
Tepeš B. Gastroezofagealna refluksna bolezen. Med Razgl 2004; 43: 261-77.
Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004; 20: 413-21.
Dias LM. Pantoprazole – a proton pump inhibitor. Clin Drug Invest 2009; Suppl 2: 3-12.
Cheer SM, Prakash A, Faulds D, et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-33.
Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England. Drug Saf 2003; 26: 121-32.
Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36: 37-47.
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe